TY  - JOUR

T1  - Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

JO  - European Urology

PY  - 2017/01/01

AU  - Parker CC

AU  - Coleman RE

AU  - Sartor O

AU  - Vogelzang NJ

AU  - Bottomley D

AU  - Heinrich D

AU  - Helle SI

AU  - O'Sullivan JM

AU  - Fosså SD

AU  - Chodacki A

AU  - Wiechno P et al

ED  - 

DO  - DOI: 10.1016/j.eururo.2017.06.021

PB  - Elsevier BV

VL  - 73

IS  - 3

SP  - 427

EP  - 435

Y2  - 2025/10/10

ER  -